E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Brain tumor (Glioblastoma) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10018336 |
E.1.2 | Term | Glioblastoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the effect on survival at 6 months of disulfiram and copper-supplement as add-on treatment in glioblastoma patients receiving alkylating chemotherapy. This will to our knowledge be the first planned RCT with disulfiram in glioblastoma patients, and will consequently serve as a proof-of concept study. |
|
E.2.2 | Secondary objectives of the trial |
To investigate in glioblastoma patients receiving alkylating chemotherapy the effect of disulfiram and copper-supplement as add-on treatment on:
- actual survival analyzed at 9, 12 and 24 months,
- median progression free survival,
- 6 and 12 month progression free survival
- median overall survival
- health-related quality of life
- volumetric expansion of the glioblastoma.
- toxicity/safety of disulfiram and copper-supplement
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. A previous diagnosis of glioblastoma (histologically verified) and presenting with a first progression/recurrence documented by MRI.
2. Indication for treatment with chemotherapeutic alkylating agents (i.e. temozolomide OR lomustine (also known as CCNU) including the so called PCV treatment (procarbazine, CCNU, vincristine)).
3. Age 18 years or older.
4. Karnofsky performance status of 60 – 100
5. Willing to refrain from ingestion of alcoholic beverages |
|
E.4 | Principal exclusion criteria |
1. Earlier treatment for progression
2. Received radiotherapy within the 3 months before the diagnosis of progression
3. History of idiopathic seizure disorder, psychosis or schizophrenia.
4. History of uncontrolled hypertension (i.e. systolic BP > 180 mmHg) or a diagnosis of congestive heart failure
5. History of active liver disease
6. History of Wilson's disease or family member with Wilson's disease (unless excluded as a carrier by genetic test).
7. Use of medications such as metronidazole, warfarin, theophylline, phenytoin, phenobarbital, chlordiazepoxide, imipramine, diazepam, isoniazid, amitriptyline within 14 days prior to the first dose of disulfiram. Of note, lorazepam and oxazepam are not affected by the P450 system and are not contraindicated with disulfiram).
8. Unfit for participation for any other reason judged by the physician including patients |
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Actual survival
- Median progression free survival
- progression free survival
- Median overall survival
- Health-related quality of life
- Volumetric expansion
- Toxicity/safety |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- at 9, 12 and 24 months (actual survival)
- at 6 and 12 months (progression free survival) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |